Dr. Richard Taubert with blood serum samples from the antibody studies on...
Dr. Richard Taubert with blood serum samples from the antibody studies on autoimmune hepatitis

© Karin Kaiser / MHH

News • Rare liver disease

New test improves diagnosis of autoimmune hepatitis

Autoimmune hepatitis (AIH) is a chronic liver inflammation that is triggered by an immunological malfunction. In this case, the immune system falsely recognises the patient's own liver cells as "foreign to the body". The symptoms of this rare liver disease are unspecific, and the exact cause is not yet known.

If left untreated, AIH can lead to abnormal scarring (fibrosis) of the liver, which can end in cirrhosis and require an organ transplant. For successful treatment, the disease must be detected as early as possible. A research team led by Dr. Richard Taubert, senior physician at the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School (MHH), has now developed a new antibody test that can be used to diagnose the disease more quickly and reliably than previous standard tests. For this purpose, the scientists examined more than 1,000 blood samples from ten European centres for liver diseases. The results have been published in the scientific journal Hepatology.

Our new test closes a diagnostic gap and helps to improve patient care

Richard Taubert

Type G antibodies - also called immunoglobulins G (IgG) - are proteins, i.e. protein compounds. The immune system sends them out to neutralise pathogens such as bacteria and viruses. In autoimmune diseases, the immunoglobulins falsely recognise their own body as foreign and are therefore called autoantibodies. "The detection of autoantibodies is an important basis for AIH diagnosis and, along with tissue examinations after liver biopsy, represents the most important diagnostic marker," says Dr Taubert.

However, the various autoantibodies detected in conventional tests so far are only of limited use for an accurate diagnosis. For one thing, they are not found in everyone who actually suffers from AIH, and for another, they can also be detected in other diseases and are therefore not specific. The research team therefore set out to find precise autoantibodies that are typical for AIH and differ from the markers for other liver diseases. In the process, they came across an unusual immunoglobulin in the blood of AIH patients. "They have the special property of being able to bind with very many human proteins," explains the gastroenterologist.

These so-called polyreactive immunoglobulins (pIgG) attach themselves, among other things, to a certain protein called HIP1R, which is found throughout the body and not only in the liver. "With this binding to HIP1R, we can detect the polyreactive immunoglobulins and use them for diagnostics," says Dr Taubert. Compared to the conventional autoantibodies that have been used to date for the diagnosis of AIH, the pIgGs are much more accurate. This means that even AIH sufferers who do not form classic autoantibodies can be detected by blood test. "Our new test closes a diagnostic gap and helps to improve patient care," emphasises the physician. With the new test, which already provides results within half a day, numerous patients with liver disease could be spared a liver biopsy. The MHH research team has already been able to test the reliability of the new test on several hundred blood samples from other member centres of the European Network for Rare Liver Diseases (ERN rare liver). The aim now is to make the test available to as many laboratories as possible. A patent has already been granted by the European Patent Office.

Source: Hannover Medical School


Read all latest stories

Related articles


News • Mental health biomarkers

Could a blood test identify suicidal thoughts?

A new US study suggests a new way to personalize mental health care: They found compounds in the blood of people with depression and suicidal ideation that could be detected using a blood test.


News • Promising biomarker found

Who will develop long Covid? It's in the blood

New research has found molecular signature differences in the blood of patients who fully recover from Covid-19 and those who develop long Covid.


News • Rapid screening diagnostic

94% accuracy: new prostate cancer blood test beats PSA method

Researchers have developed a new blood test to detect prostate cancer which displays greater accuracy than the current prostate-specific antigen (PSA) method.

Related products

Subscribe to Newsletter